Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Optibrium Introduces StarDrop 5.4 to Target Novel, Safe and Efficacious Drugs

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Next generation software adds modules for knowledge-based prediction of toxicity and application of over 20,000 bioisosteric transformations.

Optibrium announced the release of version 5.4 of its StarDrop™ software platform. This new release offers enhanced features to guide the design of novel, safe and efficacious drugs by providing access to world-leading technologies for toxicity prediction and bioisosteric transformations. These new optional modules further extend StarDrop’s capabilities to intuitively target high quality compounds in drug discovery, reducing the time and cost to deliver drug candidates with an improved chance of success.

The new Derek Nexus™ module for StarDrop, developed in collaboration with Lhasa Limited, provides knowledge-based predictions of the likelihood of a compound causing toxicity in over 40 endpoints, including mutagenicity, carcinogenicity and hepatotoxicity. Seamlessly integrated with StarDrop’s Glowing Molecule™ visualisation, this new module guides the redesign of compounds to reduce the potential for toxicity. An easy-to-use reporting feature facilitates collaboration between chemists and expert toxicologists to interpret the results, enabling effective, timely decision-making regarding the prioritisation of chemistries early in the drug discovery process.

Stimulating the search for new optimisation strategies, the BIOSTER™ module extends StarDrop’s existing Nova™ module that generates new compound ideas, prioritised against a project’s required property profile. The BIOSTER module, developed with Digital Chemistry, adds over 20,000 precedented bioisosteric transformations, which Nova can use to generate a broad range of novel structures. This database has been expertly curated from the scientific literature, with citations to the original source material facilitating further chemical and biological validation of the new ideas. The combination of Nova and BIOSTER provides access to a wealth of chemical experience to generate strategies for exploration of hits, lead hopping and patent protection.

In addition, StarDrop 5.4 also sees further enhancements of its existing functionality. The renamed torch3D module, using Cresset’s unique Field technology to understand and apply 3D Structure Activity Relationship (SAR), has been updated to include the latest version of Cresset’s XED force field providing insight into compounds’ 3D structures, biological activities and interactions. The data visualisation component of StarDrop also receives a major upgrade, introducing new interactive plot types and increased flexibility to visualise and explore structure-activity relationships.

Dr Matthew Segall, Optibrium’s CEO, commented, “We are very pleased to release this exciting new version of StarDrop, including new modules developed with our partners, so soon after announcing our collaborations with Lhasa Limited and Digital Chemistry. This reinforces our commitment to work with the wider community of developers to deliver world-leading technologies which seamlessly integrate with our unique in-house technology in StarDrop’s intuitive user interface.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optibrium Joins HeCaToS Project and Expands R&D Team
The Hepatic and Cardiac Toxicity Systems project is a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver.
Tuesday, October 08, 2013
Optibrium and Digital Chemistry Announce Technology Collaboration
Integration of bioisostere database with automatic application and prioritisation will guide the identification of successful, novel, high quality compounds in drug discovery.
Friday, December 14, 2012
Optibrium and Cresset Announce Technology Collaboration
Technology exchange combines unique methods for design of novel, high quality compounds in drug discovery.
Thursday, January 05, 2012
Scientific News
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Rare Form: Novel Structures Built from DNA Emerge
DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!